Table 2 Summary of tumor response with sunitinib plus trastuzumab
| Â | n (%) | ||||||
|---|---|---|---|---|---|---|---|
Response parameter | All patients | Treatment-naïve or prior adjuvant treatment* only | Prior first-line treatment* | Visceral disease†| Non-visceral disease | Estrogen-receptor positive | Estrogen-receptor negative |
(n = 57) | (n = 34) | (n = 23) | (n = 41) | (n = 16) | (n = 30) | (n = 27) | |
Complete response | 2 (4) | 2 (6) | 0 | 1 (2) | 1 (6) | 2 (7) | 0 |
Partial response | 19 (33) | 13 (38) | 6 (26) | 17 (41) | 2 (13) | 8 (27) | 11 (41) |
Stable disease | 21 (37) | 10 (29) | 11 (48) | 15 (37) | 6 (38) | 13 (43) | 8 (30) |
 24 weeks | 11 (19) | 5 (15) | 6 (26) | 6 (15) | 5 (31) | 6 (20) | 5 (19) |
Objective response | 21 (37) | 15 (44) | 6 (26) | 18 (44) | 3 (19) | 10 (33) | 11 (41) |
 95% exact CI | 24–51 | 27–62 | 10–48 | 28–60 | 4–46 | 17–53 | 22–61 |
Clinical benefit‡ | 32 (56) | 20 (59) | 12 (52) | 24 (59) | 8 (50) | 16 (53) | 16 (59) |
 95% exact CI | 42–69 | 41–75 | 31–73 | 42–74 | 25–75 | 34–72 | 39–78 |